

Quarterly consolidated statements of income

■Core basis

(JPY millions)

| | FY2020 | | | | | FY2021 | | | | | FY2022 |
|---------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|----------|---------------|
| | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| Revenue | 57,563 | 61,342 | 62,881 | 67,819 | 249,605 | 64,986 | 63,773 | 67,042 | 70,456 | 266,257 | 264,000 |
| YoY | -2.7% | 2.9% | -1.1% | 14.5% | 3.3% | 12.9% | 4.0% | 6.6% | 3.9% | 6.7% | -0.8% |
| Cost of sales | -24,741 | -24,964 | -26,192 | -22,324 | -98,221 | -26,924 | -25,943 | -29,837 | -26,967 | -109,671 | 103,000 |
| YoY | 2.6% | 3.2% | 0.5% | 9.0% | 3.6% | 8.8% | 3.9% | 13.9% | 20.8% | 11.7% | -6.1% |
| (Percent of revenue) | 43.0% | 40.7% | 41.7% | 32.9% | 39.4% | 41.4% | 40.7% | 44.5% | 38.3% | 41.2% | 39.0% |
| Gross profit | 32,822 | 36,377 | 36,690 | 45,495 | 151,384 | 38,062 | 37,829 | 37,205 | 43,489 | 156,586 | 161,000 |
| YoY | -6.3% | 2.6% | -2.1% | 17.4% | 3.2% | 16.0% | 4.0% | 1.4% | -4.4% | 3.4% | 2.8% |
| (Percent of revenue) | 57.0% | 59.3% | 58.3% | 67.1% | 60.6% | 58.6% | 59.3% | 55.5% | 61.7% | 58.8% | 61.0% |
| Operating profit | 11,655 | 14,035 | 10,738 | 13,673 | 50,101 | 11,713 | 12,593 | 10,247 | 11,794 | 46,348 | 45,500 |
| YoY | -8.9% | 9.3% | -13.0% | 13.5% | 0.2% | 0.5% | -10.3% | -4.6% | -13.7% | -7.5% | -1.8% |
| (Percent of revenue) | 20.2% | 22.9% | 17.1% | 20.2% | 20.1% | 18.0% | 19.7% | 15.3% | 16.7% | 17.4% | 17.2% |
| Net profit for the period | 8,807 | 10,880 | 8,653 | 9,210 | 37,549 | 9,026 | 9,530 | 7,309 | 9,330 | 35,195 | 34,100 |
| YoY | -8.9% | 19.3% | 2.9% | 6.0% | 4.6% | 2.5% | -12.4% | -15.5% | 1.3% | -6.3% | -3.1% |
| (Percent of revenue) | 15.3% | 17.7% | 13.8% | 13.6% | 15.0% | 13.9% | 14.9% | 10.9% | 13.2% | 13.2% | 12.9% |

■IFRS

(JPY millions)

| | FY2020 | | | | | FY2021 | | | | | FY2022 |
|--|---------|---------|---------|---------|---------|---------|---------|---------|---------|----------|---------------|
| | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| Revenue | 57,563 | 61,342 | 62,881 | 67,819 | 249,605 | 64,986 | 63,773 | 67,042 | 70,456 | 266,257 | 264,000 |
| YoY | -2.7% | 2.9% | -1.1% | 14.5% | 3.3% | 12.9% | 4.0% | 6.6% | 3.9% | 6.7% | -0.8% |
| Cost of sales | -24,741 | -24,964 | -26,192 | -22,324 | -98,221 | -26,924 | -25,943 | -29,837 | -26,967 | -109,671 | -103,000 |
| YoY | 2.6% | 3.2% | 0.5% | 9.0% | 3.6% | 8.8% | 3.9% | 13.9% | 20.8% | 11.7% | -6.1% |
| (Percent of revenue) | 43.0% | 40.7% | 41.7% | 32.9% | 39.4% | 41.4% | 40.7% | 44.5% | 38.3% | 41.2% | 39.0% |
| Gross profit | 32,822 | 36,377 | 36,690 | 45,495 | 151,384 | 38,062 | 37,829 | 37,205 | 43,489 | 156,586 | 161,000 |
| YoY | -6.3% | 2.6% | -2.1% | 17.4% | 3.2% | 16.0% | 4.0% | 1.4% | -4.4% | 3.4% | 2.8% |
| (Percent of revenue) | 57.0% | 59.3% | 58.3% | 67.1% | 60.6% | 58.6% | 59.3% | 55.5% | 61.7% | 58.8% | 61.0% |
| SG&A expenses | -15,551 | -17,691 | -19,579 | -26,732 | -79,554 | -20,447 | -19,205 | -20,671 | -24,176 | -84,499 | -88,500 |
| YoY | -3.1% | 1.8% | 0.9% | 30.2% | 8.4% | 31.5% | 8.6% | 5.6% | -9.6% | 6.2% | 5.5% |
| (Percent of revenue) | 27.0% | 28.8% | 31.1% | 39.4% | 31.9% | 31.5% | 30.1% | 30.8% | 34.3% | 31.7% | 33.5% |
| R&D expenses | -5,616 | -5,507 | -6,530 | -6,459 | -24,112 | -6,121 | -6,218 | -6,464 | -7,574 | -26,377 | -27,000 |
| YoY | -9.0% | 5.1% | 13.8% | 4.4% | 3.3% | 9.0% | 12.9% | -1.0% | 17.3% | 9.4% | 2.4% |
| (Percent of revenue) | 9.8% | 9.0% | 10.4% | 9.5% | 9.7% | 9.4% | 9.7% | 9.6% | 10.8% | 9.9% | 10.2% |
| Amortization on intangible assets associated with products | -2,448 | -2,430 | -2,866 | -2,907 | -10,650 | -2,421 | -2,366 | -2,468 | -2,479 | -9,734 | -10,300 |
| YoY | -1.2% | -1.2% | 15.7% | 16.7% | 7.6% | -1.1% | -2.6% | -13.9% | -14.7% | -8.6% | 5.8% |
| (Percent of revenue) | 4.3% | 4.0% | 4.6% | 4.3% | 4.3% | 3.7% | 3.7% | 3.7% | 3.5% | 3.7% | 3.9% |
| Other income | 176 | 174 | 174 | 15,483 | 16,007 | 120 | 82 | 116 | 724 | 1,043 | 500 |
| Other expenses | -1,367 | -253 | 330 | -39,599 | -40,889 | -39 | -473 | -143 | -478 | -1,133 | -1,500 |
| Operating profit | 8,016 | 10,670 | 8,219 | -14,718 | 12,187 | 9,156 | 9,650 | 7,575 | 9,505 | 35,886 | 34,200 |
| YoY | -13.3% | 9.3% | -17.2% | — | -63.7% | 14.2% | -9.6% | -7.8% | — | 194.5% | -4.7% |
| (Percent of revenue) | 13.9% | 17.4% | 13.1% | — | 4.9% | 14.1% | 15.1% | 11.3% | 13.5% | 13.5% | 13.0% |
| Finance income | 530 | 36 | 450 | 330 | 1,346 | 590 | 82 | 540 | 1,332 | 2,543 | 900 |
| Finance expenses | -187 | -695 | -264 | -341 | -1,488 | -277 | -163 | -293 | -475 | -1,209 | -600 |
| Share of loss of investments accounted for using equity method | — | -17 | -158 | -183 | -358 | -297 | -346 | -542 | -419 | -1,604 | -2,000 |
| Profit before tax | 8,359 | 9,994 | 8,247 | -14,913 | 11,688 | 9,171 | 9,222 | 7,280 | 9,944 | 35,616 | 32,500 |
| YoY | -7.1% | 6.3% | -21.9% | — | -63.6% | 9.7% | -7.7% | -11.7% | — | 204.7% | -8.7% |
| (Percent of revenue) | 14.5% | 16.3% | 13.1% | — | 4.7% | 14.1% | 14.5% | 10.9% | 14.1% | 13.4% | 12.3% |
| Income tax expenses | -2,235 | -2,420 | -1,118 | 3,211 | -2,562 | -1,845 | -2,294 | -2,238 | -2,050 | -8,427 | -8,100 |
| Net profit for the period | 6,124 | 7,575 | 7,129 | -11,702 | 9,126 | 7,326 | 6,928 | 5,042 | 7,893 | 27,189 | 24,400 |
| YoY | -4.2% | 12.4% | -0.3% | — | -58.0% | 19.6% | -8.5% | -29.3% | — | 197.9% | -10.3% |
| (Percent of revenue) | 10.6% | 12.3% | 11.3% | — | 3.7% | 11.3% | 10.9% | 7.5% | 11.2% | 10.2% | 9.2% |
| Owners of the company | 6,189 | 7,624 | 7,185 | -11,687 | 9,311 | 7,342 | 6,965 | 5,042 | 7,869 | 27,218 | 24,380 |
| Non-controlling interests | -65 | -50 | -56 | -15 | -185 | -15 | -38 | -0 | 24 | -29 | -20 |

Retroactive restatement of FY2020 figures:

The consolidated statement of financial position for FY2020 has been retroactively revised due to the completion of the allocation of consideration for acquisition of Eyeveance. The figures Q3 and Q4 in FY2020 and Q1 and Q2 in FY2021 have been updated.

Quarterly revenue details

■Revenue by business segment

(JPY millions)

| | FY2020 | | | | | FY2021 | | | | | FY2022 |
|------------------------------|--------|--------|--------|--------|---------|--------|--------|--------|--------|---------|---------------|
| | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| Prescription pharmaceuticals | 54,336 | 57,150 | 59,030 | 64,171 | 234,687 | 61,008 | 59,363 | 62,576 | 66,633 | 249,579 | 244,400 |
| YoY | 0.2% | 3.5% | -0.3% | 14.8% | 4.5% | 12.3% | 3.9% | 6.0% | 3.8% | 6.3% | -2.1% |
| OTC pharmaceuticals | 2,043 | 2,961 | 2,382 | 2,024 | 9,410 | 2,444 | 2,643 | 2,655 | 2,038 | 9,780 | 10,650 |
| YoY | -45.0% | -1.2% | -24.0% | -7.5% | -21.8% | 19.7% | -10.8% | 11.5% | 0.7% | 3.9% | 8.9% |
| Medical devices | 827 | 889 | 1,071 | 1,249 | 4,037 | 1,145 | 1,337 | 1,371 | 1,332 | 5,184 | 7,202 |
| Others | 357 | 341 | 398 | 375 | 1,471 | 389 | 431 | 441 | 453 | 1,714 | 1,748 |
| Total | 57,563 | 61,342 | 62,881 | 67,819 | 249,605 | 64,986 | 63,773 | 67,042 | 70,456 | 266,257 | 264,000 |
| YoY | -2.7% | 2.9% | -1.1% | 14.5% | 3.3% | 12.9% | 4.0% | 6.6% | 3.9% | 6.7% | -0.8% |

[Japan]

(JPY millions)

| | FY2020 | | | | | FY2021 | | | | | FY2022 |
|------------------------------|--------|--------|--------|--------|---------|--------|--------|--------|--------|---------|---------------|
| | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| Prescription pharmaceuticals | 35,078 | 36,075 | 38,992 | 45,662 | 155,807 | 38,952 | 36,723 | 40,097 | 43,933 | 159,705 | 141,700 |
| YoY | 4.4% | 3.3% | -0.9% | 11.4% | 4.7% | 11.0% | 1.8% | 2.8% | -3.8% | 2.5% | -11.3% |
| OTC pharmaceuticals | 1,975 | 2,851 | 2,303 | 1,928 | 9,058 | 2,305 | 2,486 | 2,490 | 1,904 | 9,185 | 9,400 |
| YoY | -45.7% | -2.3% | -24.7% | -8.4% | -22.7% | 16.7% | -12.8% | 8.1% | -1.2% | 1.4% | 2.3% |
| Medical devices | 645 | 690 | 784 | 806 | 2,926 | 695 | 847 | 767 | 830 | 3,139 | 3,400 |
| Others | 317 | 318 | 358 | 349 | 1,343 | 369 | 401 | 428 | 407 | 1,604 | 1,500 |
| Total | 38,016 | 39,934 | 42,438 | 48,746 | 169,133 | 42,321 | 40,456 | 43,782 | 47,074 | 173,633 | 156,000 |
| YoY | -0.7% | 2.2% | -2.4% | 10.3% | 2.5% | 11.3% | 1.3% | 3.2% | -3.4% | 2.7% | -10.2% |

[Overseas]

(JPY millions)

| | FY2020 | | | | | FY2021 | | | | | FY2022 |
|------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---------------|
| | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| Prescription pharmaceuticals | 19,258 | 21,076 | 20,037 | 18,510 | 78,880 | 22,055 | 22,640 | 22,479 | 22,699 | 89,874 | 102,700 |
| YoY | -6.8% | 3.7% | 0.8% | 24.4% | 4.1% | 14.5% | 7.4% | 12.2% | 22.6% | 13.9% | 14.3% |
| OTC pharmaceuticals | 67 | 110 | 79 | 96 | 352 | 139 | 157 | 165 | 134 | 595 | 1,250 |
| YoY | -11.2% | 40.4% | 5.1% | 15.1% | 12.7% | 106.3% | 43.0% | 109.5% | 39.5% | 69.1% | 110.2% |
| Medical devices | 182 | 199 | 287 | 443 | 1,111 | 450 | 489 | 604 | 502 | 2,046 | 3,802 |
| Others | 40 | 23 | 40 | 25 | 129 | 20 | 30 | 13 | 46 | 109 | 248 |
| Total | 19,547 | 21,408 | 20,443 | 19,074 | 80,472 | 22,665 | 23,317 | 23,261 | 23,382 | 92,624 | 108,000 |
| YoY | -6.3% | 4.1% | 1.8% | 27.0% | 5.1% | 15.9% | 8.9% | 13.8% | 22.6% | 15.1% | 16.6% |

■Revenue by region (Overseas)

(JPY millions)

| | FY2020 | | | | | FY2021 | | | | | FY2022 |
|----------------------------|--------|-------|--------|--------|--------|--------|--------|--------|--------|--------|---------------|
| | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| China | 5,806 | 6,952 | 5,570 | 5,021 | 23,349 | 6,460 | 7,556 | 6,329 | 6,852 | 27,197 | 35,000 |
| YoY | -14.0% | -0.1% | -1.6% | 70.2% | 4.6% | 11.2% | 8.7% | 13.6% | 36.5% | 16.5% | 28.7% |
| Asia (Not including China) | 3,953 | 5,244 | 4,117 | 3,902 | 17,216 | 4,600 | 4,457 | 4,641 | 6,115 | 19,813 | 23,000 |
| YoY | -11.2% | 21.6% | 5.6% | 1.8% | 4.4% | 16.4% | -15.0% | 12.7% | 56.7% | 15.1% | 16.1% |
| EMEA | 9,566 | 8,859 | 10,021 | 9,450 | 37,896 | 10,704 | 10,538 | 11,572 | 10,085 | 42,899 | 45,500 |
| YoY | 1.2% | -0.9% | -4.4% | 16.7% | 2.5% | 11.9% | 19.0% | 15.5% | 6.7% | 13.2% | 6.1% |
| Americas | 222 | 353 | 736 | 701 | 2,011 | 901 | 766 | 718 | 330 | 2,715 | 4,500 |
| YoY | 6.6% | 2.4% | — | 411.7% | 173.5% | 305.8% | 117.3% | -2.4% | -52.9% | 35.0% | 65.8% |

Quarterly revenue details

■ Revenue of major products

(JPY millions)

| Brand name (Therapeutic category) | Region | FY2020 | | | | | FY2021 | | | | | FY2022 |
|--|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---------------|
| | | Q1 | Q2 | Q3 | Q4 | Full | Q1 | Q2 | Q3 | Q4 | Full | Full Forecast |
| Cravit (Bacterial conjunctivitis) | Total | 3,291 | 4,286 | 2,874 | 2,200 | 12,650 | 3,063 | 3,797 | 2,282 | 2,570 | 11,712 | 11,852 |
| | Japan | 521 | 557 | 528 | 365 | 1,971 | 488 | 483 | 469 | 314 | 1,754 | 1,489 |
| | China | 2,186 | 2,760 | 1,661 | 1,321 | 7,927 | 1,754 | 2,661 | 1,144 | 1,406 | 6,966 | 7,195 |
| | Asia | 386 | 712 | 313 | 311 | 1,722 | 505 | 369 | 355 | 637 | 1,866 | 2,056 |
| | EMEA | 197 | 257 | 372 | 203 | 1,029 | 316 | 283 | 314 | 213 | 1,126 | 1,112 |
| Tarivid (Bacterial conjunctivitis) | Total | 319 | 598 | 288 | 222 | 1,427 | 386 | 305 | 303 | 602 | 1,596 | 1,491 |
| | Japan | 89 | 99 | 88 | 61 | 337 | 87 | 92 | 83 | 61 | 323 | 315 |
| | China | 149 | 179 | 180 | 176 | 683 | 213 | 193 | 201 | 302 | 910 | 942 |
| | Asia | 82 | 320 | 20 | -15 | 406 | 86 | 20 | 19 | 239 | 364 | 233 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Tapcom (Glaucoma) | Total | 1,529 | 1,430 | 1,683 | 1,394 | 6,036 | 1,747 | 1,693 | 1,904 | 1,627 | 6,971 | 7,577 |
| | Japan | 685 | 651 | 729 | 539 | 2,604 | 724 | 688 | 744 | 582 | 2,738 | 2,628 |
| | China | 122 | 108 | 162 | 155 | 546 | 173 | 202 | 209 | 231 | 815 | 964 |
| | Asia | 722 | 671 | 793 | 700 | 2,886 | 850 | 803 | 951 | 814 | 3,417 | 3,985 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Tapros (Glaucoma) | Total | 4,672 | 4,444 | 4,806 | 3,994 | 17,915 | 4,683 | 4,503 | 4,860 | 4,378 | 18,423 | 19,705 |
| | Japan | 2,372 | 2,233 | 2,417 | 1,687 | 8,709 | 2,281 | 2,118 | 2,256 | 1,755 | 8,409 | 7,847 |
| | China | 114 | 117 | 157 | 215 | 602 | 266 | 199 | 258 | 448 | 1,170 | 2,740 |
| | Asia | 461 | 493 | 468 | 485 | 1,907 | 490 | 493 | 518 | 576 | 2,077 | 2,051 |
| | EMEA | 1,725 | 1,602 | 1,763 | 1,606 | 6,696 | 1,646 | 1,693 | 1,828 | 1,599 | 6,767 | 7,067 |
| Cosopt (Glaucoma) | Total | 5,609 | 5,119 | 5,424 | 4,725 | 20,877 | 5,437 | 5,321 | 5,638 | 5,355 | 21,752 | 21,523 |
| | Japan | 2,042 | 1,775 | 1,851 | 1,272 | 6,940 | 1,576 | 1,442 | 1,523 | 1,108 | 5,650 | 4,898 |
| | China | 1,050 | 1,051 | 1,156 | 1,205 | 4,462 | 1,240 | 1,223 | 1,347 | 1,347 | 5,157 | 5,630 |
| | Asia | 2,516 | 2,293 | 2,417 | 2,248 | 9,475 | 2,621 | 2,656 | 2,769 | 2,900 | 10,945 | 10,995 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Timoptol *Including Timoptol XE (Glaucoma) | Total | 614 | 517 | 592 | 472 | 2,196 | 565 | 518 | 555 | 460 | 2,098 | 1,894 |
| | Japan | 322 | 295 | 311 | 210 | 1,137 | 283 | 248 | 275 | 193 | 999 | 785 |
| | China | 92 | 27 | 72 | 73 | 264 | 78 | 73 | 63 | 89 | 302 | 332 |
| | Asia | 200 | 196 | 209 | 190 | 794 | 204 | 197 | 217 | 179 | 797 | 777 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Trusopt (Glaucoma) | Total | 1,082 | 1,181 | 1,167 | 936 | 4,365 | 1,169 | 1,123 | 1,130 | 951 | 4,374 | 4,224 |
| | Japan | 350 | 320 | 331 | 226 | 1,227 | 310 | 278 | 300 | 221 | 1,108 | 965 |
| | China | 67 | 111 | 80 | 86 | 344 | 92 | 102 | 84 | 104 | 382 | 413 |
| | Asia | 664 | 750 | 756 | 623 | 2,794 | 768 | 743 | 746 | 626 | 2,883 | 2,847 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Eybelis (Glaucoma) | Total | 589 | 619 | 734 | 594 | 2,536 | 823 | 848 | 946 | 803 | 3,420 | 4,030 |
| | Japan | 589 | 619 | 734 | 574 | 2,516 | 806 | 822 | 912 | 763 | 3,304 | 3,648 |
| | China | — | — | — | 20 | 20 | 17 | 25 | 33 | 40 | 116 | 332 |
| | Asia | — | — | — | — | — | — | — | — | — | — | — |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Alesion *Including Alesion LX (Allergy) | Total | 3,047 | 4,647 | 4,978 | 20,080 | 32,752 | 5,065 | 4,502 | 4,900 | 14,925 | 29,392 | 24,074 |
| | Japan | 3,047 | 4,647 | 4,978 | 20,062 | 32,733 | 5,038 | 4,468 | 4,880 | 14,900 | 29,286 | 23,821 |
| | China | — | — | — | 19 | 19 | 28 | 34 | 20 | 25 | 106 | 253 |
| | Asia | — | — | — | — | — | — | — | — | — | — | — |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Verkazia (Vernal keratoconjunctivitis) | Total | 19 | 33 | 65 | 61 | 178 | 164 | 149 | 151 | 169 | 633 | 1,588 |
| | Japan | 17 | 28 | 61 | 57 | 162 | 155 | 137 | 133 | 159 | 585 | 743 |
| | China | 3 | 5 | 4 | 4 | 16 | 10 | 12 | 18 | 10 | 49 | 792 |
| | Asia | — | — | — | — | — | — | — | — | — | — | — |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Flumetholol (Inflammation) | Total | 650 | 817 | 654 | 691 | 2,812 | 834 | 877 | 653 | 990 | 3,354 | 3,224 |
| | Japan | 242 | 253 | 249 | 308 | 1,052 | 222 | 221 | 222 | 246 | 911 | 827 |
| | China | 325 | 485 | 263 | 319 | 1,392 | 528 | 572 | 349 | 574 | 2,023 | 1,996 |
| | Asia | 83 | 79 | 142 | 64 | 368 | 84 | 84 | 82 | 170 | 420 | 401 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Pirenoxine Ophthalmic Suspension (Senile cataract) | Total | 974 | 1,081 | 1,042 | 899 | 3,995 | 1,077 | 1,061 | 1,058 | 1,019 | 4,215 | 4,181 |
| | Japan | 616 | 629 | 666 | 481 | 2,391 | 617 | 596 | 638 | 474 | 2,326 | 2,276 |
| | China | 189 | 208 | 184 | 190 | 771 | 222 | 209 | 198 | 266 | 894 | 861 |
| | Asia | 169 | 244 | 192 | 227 | 832 | 238 | 256 | 222 | 279 | 995 | 1,044 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Oftan Catachrom (Senile cataract) | Total | 870 | 196 | 318 | 446 | 1,830 | 379 | 503 | 545 | 306 | 1,733 | 1,319 |
| | EMEA | 870 | 196 | 318 | 446 | 1,830 | 379 | 503 | 545 | 306 | 1,733 | 1,319 |
| Sodium Hyaluronate Ophthalmic Viscoelastic Preparation (Adjuvant for ophthalmic operations) | Total | 527 | 558 | 665 | 439 | 2,189 | 544 | 497 | 615 | 473 | 2,129 | 1,963 |
| | Japan | 527 | 558 | 665 | 439 | 2,189 | 544 | 497 | 615 | 473 | 2,129 | 1,963 |
| EYLEA ^{†1} (Intravitreal VEGF inhibitor) | Total | 16,802 | 16,491 | 17,662 | 13,498 | 64,454 | 18,727 | 17,748 | 19,451 | 16,558 | 72,484 | 61,896 |
| | Japan | 16,802 | 16,491 | 17,662 | 13,498 | 64,454 | 18,727 | 17,748 | 19,451 | 16,558 | 72,484 | 61,896 |
| Hyalein (Dry eye) | Total | 4,523 | 5,185 | 5,023 | 3,689 | 18,420 | 4,251 | 4,063 | 4,933 | 4,532 | 17,779 | 17,235 |
| | Japan | 1,815 | 1,789 | 1,972 | 1,392 | 6,967 | 1,721 | 1,602 | 1,797 | 1,347 | 6,466 | 5,115 |
| | China | 2,349 | 2,425 | 2,431 | 2,054 | 9,259 | 2,145 | 2,074 | 2,731 | 1,993 | 8,943 | 9,344 |
| | Asia | 359 | 972 | 620 | 243 | 2,194 | 386 | 387 | 405 | 1,192 | 2,370 | 2,776 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Diqvas (Dry eye) | Total | 3,551 | 3,558 | 4,004 | 3,291 | 14,403 | 4,537 | 4,649 | 5,063 | 4,586 | 18,835 | 24,422 |
| | Japan | 3,012 | 3,069 | 3,540 | 2,663 | 12,283 | 3,402 | 3,249 | 3,662 | 3,029 | 13,342 | 15,157 |
| | China | 71 | 172 | 167 | 307 | 717 | 697 | 983 | 958 | 1,435 | 4,074 | 6,964 |
| | Asia | 468 | 317 | 297 | 322 | 1,404 | 438 | 417 | 443 | 121 | 1,419 | 2,301 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Ikervis (Dry eye) | Total | 939 | 1,137 | 1,260 | 1,192 | 4,529 | 1,656 | 1,356 | 1,641 | 1,204 | 5,856 | 6,667 |
| | Japan | 191 | 226 | 230 | 243 | 890 | 246 | 291 | 276 | 294 | 1,106 | 1,506 |
| | China | 748 | 912 | 1,029 | 949 | 3,638 | 1,410 | 1,065 | 1,365 | 910 | 4,750 | 5,161 |
| | Asia | — | — | — | — | — | — | — | — | — | — | — |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Cationorm (Dry eye) | Total | 672 | 933 | 761 | 696 | 3,062 | 829 | 806 | 902 | 693 | 3,230 | 3,785 |
| | Japan | 71 | 54 | 74 | 57 | 256 | 103 | 82 | 173 | 109 | 467 | 406 |
| | China | 438 | 586 | 470 | 475 | 1,969 | 532 | 536 | 563 | 448 | 2,078 | 2,458 |
| | Asia | 163 | 293 | 218 | 165 | 838 | 194 | 188 | 165 | 137 | 685 | 920 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |
| Lentis comfort (Intraocular Lens for Cataract Treatment) | Total | 215 | 250 | 364 | 367 | 1,196 | 341 | 327 | 391 | 363 | 1,422 | 1,742 |
| | Japan | 215 | 250 | 364 | 367 | 1,196 | 341 | 327 | 391 | 363 | 1,422 | 1,742 |
| PRESERFLO MicroShunt (Glaucoma implant device) | Total | 174 | 182 | 273 | 263 | 892 | 347 | 381 | 439 | 445 | 1,612 | 2,398 |
| | EMEA | 174 | 182 | 273 | 263 | 892 | 347 | 381 | 439 | 445 | 1,612 | 2,364 |
| OTC pharmaceuticals | Total | 2,043 | 2,961 | 2,382 | 2,024 | 9,410 | 2,444 | 2,643 | 2,655 | 2,038 | 9,780 | 10,650 |
| | Japan | 1,975 | 2,851 | 2,303 | 1,928 | 9,058 | 2,305 | 2,486 | 2,490 | 1,904 | 9,185 | 9,400 |
| | China | — | — | — | — | — | — | — | — | 7 | 7 | 650 |
| | Asia | 67 | 110 | 79 | 96 | 352 | 139 | 157 | 165 | 127 | 588 | 600 |
| | EMEA | — | — | — | — | — | — | — | — | — | — | — |

^{†1} Co-promoted product of Bayer Yakuhin, Ltd. (MAH)

Note: Forecasts in this report are based on currently available information. Actual results may differ materially depending on a number of factors including business environment change and others. Our full-year forecasts are based on our foreign exchange assumptions. Revenue by region shows that of major countries or regions.